News | January 02, 2025
Akums commissions new manufacturing facility for Lyophilized and Sterile dosage
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Subscribe To Our Newsletter & Stay Updated
